X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs GSK PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. GSK PHARMA WOCKHARDT LTD./
GSK PHARMA
 
P/E (TTM) x -19.2 60.6 - View Chart
P/BV x 2.0 11.3 18.0% View Chart
Dividend Yield % 0.0 2.5 0.1%  

Financials

 WOCKHARDT LTD.   GSK PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
GSK PHARMA
Mar-18
WOCKHARDT LTD./
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0122,760 36.7%   
Low Rs5322,040 26.1%   
Sales per share (Unadj.) Rs355.9339.0 105.0%  
Earnings per share (Unadj.) Rs-60.341.4 -145.5%  
Cash flow per share (Unadj.) Rs-46.845.9 -101.9%  
Dividends per share (Unadj.) Rs0.0135.00 0.0%  
Dividend yield (eoy) %01.5 0.1%  
Book value per share (Unadj.) Rs257.8242.9 106.1%  
Shares outstanding (eoy) m110.6384.70 130.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.27.1 30.6%   
Avg P/E ratio x-12.857.9 -22.1%  
P/CF ratio (eoy) x-16.552.3 -31.6%  
Price / Book Value ratio x3.09.9 30.3%  
Dividend payout %084.5 -0.0%   
Avg Mkt Cap Rs m85,379203,280 42.0%   
No. of employees `0006.3NA-   
Total wages/salary Rs m9,3715,234 179.0%   
Avg. sales/employee Rs Th6,295.0NM-  
Avg. wages/employee Rs Th1,498.3NM-  
Avg. net profit/employee Rs Th-1,066.3NM-  
INCOME DATA
Net Sales Rs m39,36928,715 137.1%  
Other income Rs m1,202545 220.4%   
Total revenues Rs m40,57129,260 138.7%   
Gross profit Rs m185,059 0.4%  
Depreciation Rs m1,495380 393.5%   
Interest Rs m2,5552 127,745.0%   
Profit before tax Rs m-2,8305,222 -54.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582178 -2,012.3%   
Tax Rs m2571,892 13.6%   
Profit after tax Rs m-6,6693,508 -190.1%  
Gross profit margin %017.6 0.3%  
Effective tax rate %-9.136.2 -25.1%   
Net profit margin %-16.912.2 -138.6%  
BALANCE SHEET DATA
Current assets Rs m33,79621,815 154.9%   
Current liabilities Rs m26,91715,999 168.2%   
Net working cap to sales %17.520.3 86.3%  
Current ratio x1.31.4 92.1%  
Inventory Days Days7964 124.8%  
Debtors Days Days8919 477.5%  
Net fixed assets Rs m39,66412,475 318.0%   
Share capital Rs m553847 65.3%   
"Free" reserves Rs m27,96819,726 141.8%   
Net worth Rs m28,52220,573 138.6%   
Long term debt Rs m21,7316 362,185.0%   
Total assets Rs m81,62039,475 206.8%  
Interest coverage x-0.12,612.0 -0.0%   
Debt to equity ratio x0.80 261,253.3%  
Sales to assets ratio x0.50.7 66.3%   
Return on assets %-5.08.9 -56.7%  
Return on equity %-23.417.1 -137.1%  
Return on capital %-7.726.2 -29.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,807564 1,738.8%   
Fx outflow Rs m1,7897,429 24.1%   
Net fx Rs m8,019-6,865 -116.8%   
CASH FLOW
From Operations Rs m6844,728 14.5%  
From Investments Rs m6,302-1,042 -604.9%  
From Financial Activity Rs m-7,695-3,066 250.9%  
Net Cashflow Rs m-664620 -107.1%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 2.3 10.2 22.5%  
FIIs % 7.7 23.8 32.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 15.4 100.0%  
Shareholders   67,757 102,036 66.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 150 Points Up; Oil & Gas Stocks Lead(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares show losses. The Nikkei 225 is up 0.3% while the Hang Seng is down 0.1%.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Nov 14, 2018 11:57 AM

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS